Gaboxadol: Gaboxadol (THIP) is a direct-acting GABA-A receptor agonist developed by Lundbeck and Merck as an experimental sleep aid. Clinical trials were discontinued in 2007 due to narrow therapeutic index and psychiatric side effects at effective doses. Unlike benzodiazepines, it acts as an orthos
Related pages